S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Stock ideas from the 2024 Microcap Conference
Critical asset just had biggest fall on record (Ad)
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
How major US stock indexes fared Friday, 2/23/2024
U.S. "Shadow Banks" About to Blow up again? (Ad)
In his annual letter, Warren Buffett tells investors to ignore Wall Street pundits
MarketBeat Week in Review – 2/19 - 2/23
U.S. "Shadow Banks" About to Blow up again? (Ad)
Closing prices for crude oil, gold and other commodities
Mark Zuckerberg Is Sitting on a Huge Stockpile of AI Chips as Companies Compete for Limited Supplies
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Stock ideas from the 2024 Microcap Conference
Critical asset just had biggest fall on record (Ad)
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
How major US stock indexes fared Friday, 2/23/2024
U.S. "Shadow Banks" About to Blow up again? (Ad)
In his annual letter, Warren Buffett tells investors to ignore Wall Street pundits
MarketBeat Week in Review – 2/19 - 2/23
U.S. "Shadow Banks" About to Blow up again? (Ad)
Closing prices for crude oil, gold and other commodities
Mark Zuckerberg Is Sitting on a Huge Stockpile of AI Chips as Companies Compete for Limited Supplies
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Stock ideas from the 2024 Microcap Conference
Critical asset just had biggest fall on record (Ad)
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
How major US stock indexes fared Friday, 2/23/2024
U.S. "Shadow Banks" About to Blow up again? (Ad)
In his annual letter, Warren Buffett tells investors to ignore Wall Street pundits
MarketBeat Week in Review – 2/19 - 2/23
U.S. "Shadow Banks" About to Blow up again? (Ad)
Closing prices for crude oil, gold and other commodities
Mark Zuckerberg Is Sitting on a Huge Stockpile of AI Chips as Companies Compete for Limited Supplies
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Stock ideas from the 2024 Microcap Conference
Critical asset just had biggest fall on record (Ad)
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
How major US stock indexes fared Friday, 2/23/2024
U.S. "Shadow Banks" About to Blow up again? (Ad)
In his annual letter, Warren Buffett tells investors to ignore Wall Street pundits
MarketBeat Week in Review – 2/19 - 2/23
U.S. "Shadow Banks" About to Blow up again? (Ad)
Closing prices for crude oil, gold and other commodities
Mark Zuckerberg Is Sitting on a Huge Stockpile of AI Chips as Companies Compete for Limited Supplies

Amylyx Pharmaceuticals (AMLX) Earnings Date, Estimates & Call Transcripts

$17.65
-0.89 (-4.80%)
(As of 02/23/2024 ET)

Earnings Summary

Upcoming
Earnings Date
May. 9Estimated
Actual EPS
(Feb. 22)
$0.23 Beat By $0.03
Consensus EPS
(Feb. 22)
$0.20
Skip Charts & View Estimated and Actual Earnings Data

AMLX Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

AMLX Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Amylyx Pharmaceuticals Analyst EPS Estimates

Current Year EPS Consensus Estimate:$1.55 EPS
Next Year EPS Consensus Estimate: $1.44 EPS

AMLX Earnings Date and Information

Amylyx Pharmaceuticals last issued its quarterly earnings results on February 22nd, 2024. The reported $0.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.20 by $0.03. The firm earned $108.45 million during the quarter, compared to the consensus estimate of $106.40 million. Amylyx Pharmaceuticals has generated $0.70 earnings per share over the last year ($0.70 diluted earnings per share) and currently has a price-to-earnings ratio of 25.2. Earnings for Amylyx Pharmaceuticals are expected to decrease by -7.10% in the coming year, from $1.55 to $1.44 per share. Amylyx Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 9th, 2024 based off prior year's report dates.

Amylyx Pharmaceuticals Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/9/2024
Estimated)
------- 
2/22/2024Q4 2023$0.20$0.23+$0.03$0.07$106.40 million$108.45 million    
11/9/2023Q3 2023$0.42$0.30($0.12)$0.30$113.95 million$102.69 million
8/10/2023Q2 2023$0.01$0.31+$0.30$0.31$84.30 million$98.22 million
5/11/2023Q1 2023($0.27)$0.02+$0.29$0.02$57.35 million$71.43 million
3/13/2023Q4 2022($0.77)($0.65)+$0.12($0.65)$3.05 million$21.89 million    
11/10/2022Q3 2022($0.97)($0.92)+$0.05($0.92)-$0.35 million
8/11/2022Q2 2022($0.92)($0.93)($0.01)($0.93)--
5/12/2022Q1 2022($0.75)($0.93)($0.18)($0.93)--












Amylyx Pharmaceuticals Earnings - Frequently Asked Questions

When is Amylyx Pharmaceuticals's earnings date?

Amylyx Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 9th, 2024 based off last year's report dates. Learn more on AMLX's earnings history.

Did Amylyx Pharmaceuticals beat their earnings estimates last quarter?

In the previous quarter, Amylyx Pharmaceuticals (NASDAQ:AMLX) reported $0.23 earnings per share (EPS) to beat the analysts' consensus estimate of $0.20 by $0.03. Learn more on analysts' earnings estimate vs. AMLX's actual earnings.

How can I listen to Amylyx Pharmaceuticals's earnings conference call?

The conference call for Amylyx Pharmaceuticals's latest earnings report can be listened to online. Listen to Conference Call

How can I read Amylyx Pharmaceuticals's conference call transcript?

The conference call transcript for Amylyx Pharmaceuticals's latest earnings report can be read online. Read Transcript

How much revenue does Amylyx Pharmaceuticals generate each year?

Amylyx Pharmaceuticals (NASDAQ:AMLX) has a recorded annual revenue of $380.79 million.

How much profit does Amylyx Pharmaceuticals generate each year?

Amylyx Pharmaceuticals (NASDAQ:AMLX) has a recorded net income of -$198.38 million. AMLX has generated $0.70 earnings per share over the last four quarters.

What is Amylyx Pharmaceuticals's price-to-earnings ratio?

Amylyx Pharmaceuticals (NASDAQ:AMLX) has a trailing price-to-earnings ratio of 25.21 and a forward price-to-earnings ratio of 11.39. The price/earnings-to-growth ratio is 0.18.

What is Amylyx Pharmaceuticals's EPS forecast for next year?

Amylyx Pharmaceuticals's earnings are expected to decrease from $1.55 per share to $1.44 per share in the next year, which is a -7.10% change.


More Earnings Resources from MarketBeat

This page (NASDAQ:AMLX) was last updated on 2/24/2024 by MarketBeat.com Staff